ストックスクリーナーアプリを入手
5.28
3.73%
0.19
アフターアワーズ：
5.28
前日終値:
$5.09
開ける：
$5.02
24時間の取引高:
66,483
Relative Volume:
2.34
時価総額：
$42.22M
収益：
$85,000
当期純損益:
$-22.16M
株価収益率:
-0.1402
EPS:
-37.672
ネットキャッシュフロー:
$-6.29M
1週間 パフォーマンス:
+7.32%
1か月 パフォーマンス:
+4.76%
6か月 パフォーマンス:
-49.71%
1年 パフォーマンス:
-60.38%
1日の値動き範囲:
$4.90
$5.38
1週間の範囲:
$4.90
$5.65
52週間の値動き範囲:
$3.85
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Compare PAVM vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
5.28 | 41.42M | 85,000 | -22.16M | -6.29M | -37.67 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-05 | 開始されました | Ascendiant Capital Markets | Buy |
| 2018-06-28 | 開始されました | Maxim Group | Buy |
Pavmed Inc (PAVM) 最新ニュース
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Q1 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
PAVmed Inc. Series Z Warrant (PAVMZ) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
PAVmed Inc (PAVMW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Completion of Louisville VA Medical Center delayed until 2027 - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the ClosePost-Earnings Reaction - vinanet.vn
WVU PCH updates their signage and navigation - AOL.com
VA touts psilocybin trial for vets, but relief could take time - AOL.com
Verasonics Appoints New Senior Vice President, Research & Development - AOL.com
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfitability Analysis - vinanet.vn
Former President of DePuy Synthes U.S. Joins Peptilogics Board - AOL.com
PAVmed Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-08-17 - Seeking Alpha
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVM Q1 2026 Earnings: EPS of -$4.42 Misses Consensus by 519%; Shares Rally 9.7%ROA Comparison - vinanet.vn
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan
PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative
PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter - AOL.com
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine
PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
Pavmed Inc (PAVM) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.13%
大文字化:
|
ボリューム (24 時間):